Cancer Genetics Inc., a Rutherford maker of cancer diagnostics tests, has announced the closing of its previously announced public offering of 1.5 million shares of its common stock at $10 per share.
The gross proceeds to Cancer Genetics from the offering, first announced last week, were $15 million before underwriting discounts and commissions and other offering expenses payable by Cancer Genetics, according to the announcement. The company has also granted the representative of the underwriters a 45-day option to purchase up to 225,000 additional shares of common stock from Cancer Genetics to cover over-allotments, if any.
Aegis Capital Corp. acted as sole book-running manager for the offering, while Feltl and Company, Inc. acted as co-lead manager for the offering, the company said in its statement.
Digital content editor Joe Ross is @joeross on Twitter.